169 related articles for article (PubMed ID: 34409743)
21. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study.
Kruger S; Haas M; Burkl C; Goehring P; Kleespies A; Roeder F; Gallmeier E; Ormanns S; Westphalen CB; Heinemann V; Rank A; Boeck S
Thromb Res; 2017 Sep; 157():9-15. PubMed ID: 28675831
[TBL] [Abstract][Full Text] [Related]
22. Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients With Hepatocellular Carcinoma.
Wang Y; Attar BM; Fuentes HE; Yu J; Zhang H; Tafur AJ
Clin Appl Thromb Hemost; 2018 Apr; 24(3):471-476. PubMed ID: 28288526
[TBL] [Abstract][Full Text] [Related]
23. The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study.
Overvad TF; Skjøth F; Piazza G; Noble S; Ording AG; Larsen TB; Nielsen PB
J Thromb Haemost; 2022 Dec; 20(12):2921-2929. PubMed ID: 36112135
[TBL] [Abstract][Full Text] [Related]
24. Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy.
Overvad TF; Ording AG; Nielsen PB; Skjøth F; Albertsen IE; Noble S; Vistisen AK; Gade IL; Severinsen MT; Piazza G; Larsen TB
Blood Adv; 2022 May; 6(10):2967-2976. PubMed ID: 35045569
[TBL] [Abstract][Full Text] [Related]
25. Postoperative venous thromboembolism risk stratification in patients with uterine cancer.
Wagner VM; Piver RN; Levine MD; Backes FJ; Chambers LJ; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Bixel KL
Am J Obstet Gynecol; 2023 May; 228(5):555.e1-555.e8. PubMed ID: 36574873
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients.
Schorling RM; Pfrepper C; Golombek T; Cella CA; Muñoz-Unceta N; Siegemund R; Engel C; Petros S; Lordick F; Knödler M
Oncol Res Treat; 2020; 43(9):414-427. PubMed ID: 32580190
[TBL] [Abstract][Full Text] [Related]
27. Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data.
Tsubata Y; Kawakado K; Hamai K; Furuya N; Yokoyama T; Saito R; Nakamura A; Masuda T; Hamaguchi M; Kuyama S; Honda R; Senoo T; Nakanishi M; Hotta T; Yamasaki M; Ishikawa N; Fujitaka K; Kubota T; Kobayashi K; Isobe T
Int J Clin Oncol; 2023 Jan; 28(1):69-78. PubMed ID: 36357710
[TBL] [Abstract][Full Text] [Related]
28. COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study.
Abdel-Razeq H; Sharaf B; Al-Jaghbeer MJ; Abu-Fares H; Bater R; Shaer MA; Abu-Jaish H; Laban DA; Salamah O; Tamimi F; Ashouri K; Salameh T; Zughul R; Alhalaseh Y
J Thromb Thrombolysis; 2023 Oct; 56(3):447-453. PubMed ID: 37430158
[TBL] [Abstract][Full Text] [Related]
29. Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.
Alma S; Eloi D; Léa V; Julie C; Valérie M; Pierre G; Hilgers W; Philippe G; Christine Z; Philippe D
J Thromb Thrombolysis; 2022 Aug; 54(2):287-294. PubMed ID: 35396660
[TBL] [Abstract][Full Text] [Related]
30. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy.
Ramos JD; Casey MF; Bamias A; De Giorgi U; Bellmunt J; Harshman LC; Ladoire S; Wong YN; Alva AS; Rosenberg JE; Galsky MD; Yu EY;
Clin Appl Thromb Hemost; 2017 Oct; 23(7):755-760. PubMed ID: 27637910
[TBL] [Abstract][Full Text] [Related]
31. Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study.
Kraaijpoel N; van Es N; Raskob GE; Büller HR; Carrier M; Zhang G; Lin M; Grosso MA; Di Nisio M
Thromb Haemost; 2018 Jul; 118(7):1270-1278. PubMed ID: 29864787
[TBL] [Abstract][Full Text] [Related]
32. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.
Pépin M; Kleinjan A; Hajage D; Büller HR; Di Nisio M; Kamphuisen PW; Salomon L; Veyradier A; Stepanian A; Mahé I
J Thromb Haemost; 2016 Feb; 14(2):306-15. PubMed ID: 26589836
[TBL] [Abstract][Full Text] [Related]
33. Performance of Current Thromboembolism Risk Assessment Tools in Patients With Gastric Cancer and Validity After First Treatment.
Fuentes HE; Paz LH; Wang Y; Oramas DM; Simons CR; Tafur AJ
Clin Appl Thromb Hemost; 2018 Jul; 24(5):790-796. PubMed ID: 28884610
[TBL] [Abstract][Full Text] [Related]
34. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis.
Mulder FI; Candeloro M; Kamphuisen PW; Di Nisio M; Bossuyt PM; Guman N; Smit K; Büller HR; van Es N;
Haematologica; 2019 Jun; 104(6):1277-1287. PubMed ID: 30606788
[TBL] [Abstract][Full Text] [Related]
35. Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer.
Shaw JR; Kumar V; Mallick R; Carrier M; Ilich A; Key NS; Wells P
Thromb Res; 2020 Dec; 196():437-443. PubMed ID: 33065408
[TBL] [Abstract][Full Text] [Related]
36. Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Riedl JM; Schwarzenbacher E; Moik F; Horvath L; Gantschnigg A; Renneberg F; Posch F; Barth DA; Stotz M; Pichler M; Hatzl S; Fandler-Höfler S; Gressenberger P; Gary T; Jost PJ; Greil R; Ay C; Djanani A; Gerger A; Schlick K
Thromb Haemost; 2022 Apr; 122(4):633-645. PubMed ID: 34255340
[TBL] [Abstract][Full Text] [Related]
37. Influence of type 2 diabetes mellitus on Khorana venous thromboembolism risk in colorectal cancer patients.
Wang R; Liu R; Zhao L; Xu D; Hu L
Rev Esp Enferm Dig; 2017 Jul; 109(7):503-509. PubMed ID: 28593781
[TBL] [Abstract][Full Text] [Related]
38. PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL).
Santi RM; Ceccarelli M; Catania G; Monagheddu C; Evangelista A; Bernocco E; Monaco F; Federico M; Vitolo U; Cortelazzo S; Cabras MG; Spina M; Baldini L; Boccomini C; Chiappella A; Bari A; Luminari S; Calabrese M; Levis A; Visco C; Contino L; Ciccone G; Ladetto M
Thromb Res; 2016 Apr; 140 Suppl 1():S177. PubMed ID: 27161692
[TBL] [Abstract][Full Text] [Related]
39. Identification of risk factors for venous thromboembolism and evaluation of Khorana venous thromboembolism risk assessment in Japanese lung cancer patients.
Hiraide M; Shiga T; Minowa Y; Nakano Y; Yoshioka H; Suzuki K; Yasuda C; Takahashi H; Hama T
J Cardiol; 2020 Jan; 75(1):110-114. PubMed ID: 31416782
[TBL] [Abstract][Full Text] [Related]
40. Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort.
Verzeroli C; Giaccherini C; Russo L; Bolognini S; Gamba S; Tartari CJ; Schieppati F; Ticozzi C; Vignoli A; Masci G; Sarmiento R; Spinelli D; Malighetti P; Tondini C; Petrelli F; Giuliani F; D'Alessio A; Gasparini G; Minelli M; De Braud F; Santoro A; Labianca R; Marchetti M; Falanga A;
J Thromb Haemost; 2023 Jul; 21(7):1869-1881. PubMed ID: 37054917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
